Cancer continues to be a substantial global health issue. By customizing prevention, diagnosis, and treatment plans depending on individual patient genetic ...

U.S. investment in new treatments is often driven by market potential rather than medical necessity, deepening health ...

In April, 2025, Demis Hassabis, the Nobel Prize-winning CEO of Google DeepMind, appeared on the US television show 60 Minutes and suggested that all diseases could be curable with the help of ...

Medico-Legal Regulation Of Clinical Trials In IndiaMedical innovation, research and development are a necessary arm for the ...

AI was supposed to boost drug discovery, but progress has stalled. Learn why the hype hasn’t delivered and what needs to ...

Drug metabolism is the process by which living organisms modify pharmaceutical substances through specialized enzymatic ...

The rapid emergence and re-emergence of viral pathogens—exemplified by outbreaks of influenza, Ebola, Zika, and, most recently, SARS-CoV-2—underscore the ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

AI in Cancer Drug Discovery could prove paradigm shifting, but what challenges does it present? And how can they be avoided?

Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several ...

We need a dedicated framework that clarifies the rules, requirements and incentives for those building personalized ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...